Heart drug HRS-1893 safety check: 300 patients monitored Long-Term
NCT ID NCT07021963
First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 31 times
Summary
This study looks at the long-term safety of a drug called HRS-1893 in 300 people with hypertrophic cardiomyopathy, a condition where the heart muscle thickens. Participants must have taken HRS-1893 in a previous study. Researchers will track side effects and heart function over time to see if the drug remains safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTROPHIC CARDIOMYOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
RECRUITINGBeijing, Beijing Municipality, 100037, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.